Duration of fever in children infected with influenza A(H1N1)pdm09, A (H3N2) or B virus and treated with baloxavir marboxil, oseltamivir, laninamivir, or zanamivir in Japan during the 2012-2013 and 2019-2020 influenza seasons

被引:1
作者
Sun, Yuyang [1 ]
Wagatsuma, Keita [1 ]
Saito, Reiko [1 ]
Sato, Isamu [2 ]
Kawashima, Takashi [3 ]
Saito, Tadashi [4 ]
Shimada, Yashushi [5 ]
Ono, Yasuhiko [6 ]
Kakuya, Fujio [7 ]
Minato, Michiyoshi [8 ]
Kodo, Naoki [9 ]
Suzuki, Eitaro [10 ]
Kitano, Akito [11 ]
Chon, Irina [1 ]
Phyu, Wint Wint [1 ]
Li, Jiaming [1 ]
Watanabe, Hisami [12 ]
机构
[1] Niigata Univ, Grad Sch Med & Dent Sci, Div Int Hlth Publ Hlth, Niigata, Japan
[2] Yoiko Pediat Clin, Niigata, Japan
[3] Kawashima Internal Med Clin, Gunma, Japan
[4] Tako Cent Hosp, Chiba, Japan
[5] Shimada Childrens Clin, Kumamoto, Japan
[6] Ono Pediat Clin, Nagasaki, Japan
[7] Furano Kyokai Hosp, Furano, Hokkaido, Japan
[8] Miyata Pediat Clin, Tokyo, Japan
[9] Kodo Pediat Clin, Kyoto, Japan
[10] Suzuki Pediat Clin, Yamaguchi, Japan
[11] Kitano Pediat Clin, Kumamoto, Japan
[12] Niigata Univ, Niigata Univ Myanmar IDRC, Grad Sch Med & Dent Sci, Infect Dis Res Ctr, Niigata, Japan
关键词
Baloxavir marboxil; Neuraminidase inhibitors; Influenza virus; Antiviral treatment; Clinical effectiveness; A H3N2; RESISTANCE; EMERGENCE;
D O I
10.1016/j.antiviral.2024.105938
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We compared the duration of fever in children infected with A(H1N1)pdm09, A(H3N2), or influenza B viruses following treatment with baloxavir marboxil (baloxavir) or neuraminidase inhibitors (NAIs) (oseltamivir, zanamivir, or laninamivir). This observational study was conducted at 10 outpatient clinics across 9 prefectures in Japan during the 2012-2013 and 2019-2020 influenza seasons. Patients with influenza rapid antigen test positive were treated with one of four anti-influenza drugs. The type/subtype of influenza viruses were identified from MDCK or MDCK SIAT1 cell-grown samples using two-step real-time PCR. Daily self-reported body temperature after treatment were used to evaluate the duration of fever by treatment group and various underlying factors. Among 1742 patients <19 years old analyzed, 452 (26.0%) were A(H1N1)pdm09, 827 (48.0%) A (H3N2), and 463 (26.0%) influenza B virus infections. Among fours treatment groups, baloxavir showed a shorter median duration of fever compared to oseltamivir in univariate analysis for A(H1N1)pdm09 virus infections (baloxavir, 22.0 h versus oseltamivir, 26.7 h, P < 0.05; laninamivir, 25.5 h, and zanamivir, 25.0 h). However, this difference was not significant in multivariable analyses. For A(H3N2) virus infections, there were no statistically significant differences observed (20.3, 21.0, 22.0, and 19.0 h) uni- and multivariable analyses. For influenza B, baloxavir shortened the fever duration by approximately 15 h than NAIs (20.3, 35.0, 34.3, and 34.1 h), as supported by uni- and multivariable analyses. Baloxavir seems to have comparable clinical effectiveness with NAIs on influenza A but can be more effective for treating pediatric influenza B virus infections than NAIs.
引用
收藏
页数:9
相关论文
共 43 条
[1]  
Ali ST, 2022, LANCET GLOB HEALTH, V10, pE1612, DOI 10.1016/S2214-109X(22)00358-8
[2]  
[Anonymous], 2020, Influenza Surveillance Report, F.
[3]   Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2) [J].
Baker, Jeffrey ;
Block, Stanley L. ;
Matharu, Balpreet ;
Burleigh Macutkiewicz, Laura ;
Wildum, Steffen ;
Dimonaco, Sophie ;
Collinson, Neil ;
Clinch, Barry ;
Piedra, Pedro A. .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2020, 39 (08) :700-705
[4]   Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season [J].
Baranovich, Tatiana ;
Saito, Reiko ;
Suzuki, Yasushi ;
Zaraket, Hassan ;
Dapat, Clyde ;
Caperig-Dapat, Isolde ;
Oguma, Taeko ;
Shabana, Iman Ibrahim ;
Saito, Takehiko ;
Suzuki, Hiroshi .
JOURNAL OF CLINICAL VIROLOGY, 2010, 47 (01) :23-28
[5]   Sialylated and sulfated N-Glycans in MDCK and engineered MDCK cells for influenza virus studies [J].
Byrd-Leotis, Lauren ;
Jia, Nan ;
Matsumoto, Yasuyuki ;
Lu, Dongli ;
Kawaoka, Yoshihiro ;
Steinhauer, David A. ;
Cummings, Richard D. .
SCIENTIFIC REPORTS, 2022, 12 (01)
[6]   Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019-2020 influenza season [J].
Chong, Yong ;
Kawai, Naoki ;
Tani, Naoki ;
Bando, Takuma ;
Takasaki, Yoshio ;
Shindo, Shizuo ;
Ikematsu, Hideyuki .
ANTIVIRAL RESEARCH, 2021, 192
[7]   Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan [J].
Dapat, Clyde ;
Kondo, Hiroki ;
Dapat, Isolde C. ;
Baranovich, Tatiana ;
Suzuki, Yasushi ;
Shobugawa, Yugo ;
Saito, Kousuke ;
Saito, Reiko ;
Suzuki, Hiroshi .
ANTIVIRAL RESEARCH, 2013, 99 (03) :261-269
[8]   Epidemiology of Human Influenza A and B Viruses in Myanmar from 2005 to 2007 [J].
Dapat, Clyde ;
Saito, Reiko ;
Kyaw, Yadanar ;
Naito, Makoto ;
Hasegawa, Go ;
Suzuki, Yasushi ;
Dapat, Isolde C. ;
Zaraket, Hassan ;
Cho, Tin Maung ;
Li, Danjuan ;
Oguma, Taeko ;
Baranovich, Tatiana ;
Suzuki, Hiroshi .
INTERVIROLOGY, 2009, 52 (06) :310-320
[9]   Genetic Characterization of Human Influenza Viruses in the Pandemic (2009-2010) and Post-Pandemic (2010-2011) Periods in Japan [J].
Dapat, Isolde C. ;
Dapat, Clyde ;
Baranovich, Tatiana ;
Suzuki, Yasushi ;
Kondo, Hiroki ;
Shobugawa, Yugo ;
Saito, Reiko ;
Suzuki, Hiroshi .
PLOS ONE, 2012, 7 (06)
[10]  
Gordis L., 2014, Epidemiology, V5